Buys
Open market- Shares
- Avg price
- Total value
Mark Jeffrey DeLong - Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc.
Issuer-level insider activity
- Role
- Chief Business & Strat Officer
- Issuer ticker
- APLS
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Mark Jeffrey DeLong in Apellis Pharmaceuticals, Inc.
Sells
Open market- Shares
- -6,853
- Avg price
- $21.51
- Total value
- -$147,421
Net
Past year- Shares
- -6,853
- Share %
- -100%
- Total value
- -$147,421
Reported holdings for Mark Jeffrey DeLong in Apellis Pharmaceuticals, Inc.
Form 4 holding
Chief Business & Strat Officer
Apellis Pharmaceuticals, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 0
- Estimated value
- $1,599,675
- Report date
- 14 May 2026
- Price
- $19.39
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Business & Strat Officer
Apellis Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 14 May 2026
- Price
- $40.23
- Ownership
- Direct
Transaction history for Mark Jeffrey DeLong in Apellis Pharmaceuticals, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.